Last mentioned: 2d ago
Missouri Pause Request
DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
Public Confirmation
Stryker issues official statements confirming the disruption and the ongoing forensic investigation.
Group Claims Responsibility
The Iran-linked group Handala publicly claims responsibility for the attack on social media platforms.
Network Shutdown
Company initiates a global shutdown of internal networks to contain the spread of suspected wiper malware.
Initial Detection
Stryker IT security teams detect unauthorized access and anomalous activity on global servers.
Hawley Federal Bill
Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
Heartbeat Ban Enacted
Wyoming implements new restrictions based on detectable fetal cardiac activity.
Louisiana Pause Request
DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
Missouri Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.
Judicial Injunction
State courts maintain blocks on previous total and medication-specific abortion bans.
Medication Ban Attempt
Wyoming Governor signs the first U.S. law specifically banning abortion pills.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to states.
The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
Medical technology giant Stryker (SYK) has confirmed a massive cyberattack that has disrupted its global networks and forced the closure of its Michigan headquarters. The attack, attributed to the Iran-linked group Handala, reportedly involves destructive wiper malware targeting the company's critical infrastructure.
Wyoming has implemented a ban on abortions once a fetal heartbeat is detected, significantly narrowing the window for legal procedures and medication access. The move triggers immediate concerns for healthcare providers and sets the stage for a protracted legal battle over reproductive rights and pharmaceutical distribution.